Report cover image

Global HER2 Antibody Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 191 Pages
SKU # APRC20280342

Description

Summary

According to APO Research, the global HER2 Antibody market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for HER2 Antibody is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for HER2 Antibody is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the HER2 Antibody market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for HER2 Antibody is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the HER2 Antibody market include Novartis AG, Pfizer, InvivoGen, Genentech Inc, Celltrion, Bio-Techne, Biocon Limited and Abnova Corporation, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for HER2 Antibody, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of HER2 Antibody, also provides the value of main regions and countries. Of the upcoming market potential for HER2 Antibody, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the HER2 Antibody revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global HER2 Antibody market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global HER2 Antibody company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
HER2 Antibody Segment by Company

Novartis AG
Pfizer
InvivoGen
Genentech Inc
Celltrion
Bio-Techne
Biocon Limited
Abnova Corporation
HER2 Antibody Segment by Type

Ado-trastuzumab Emtansine
Lapatinib
Pertuzumab
Trastuzumab
Everolimus
HER2 Antibody Segment by Application

Hospital
Medical Center
HER2 Antibody Segment by Region

North America

United States
Canada
Europe

Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Middle East & Africa

Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global HER2 Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the HER2 Antibody key companies, revenue, market share, and recent developments.
3. To split the HER2 Antibody breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions HER2 Antibody market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify HER2 Antibody significant trends, drivers, influence factors in global and regions.
6. To analyze HER2 Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HER2 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of HER2 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HER2 Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global HER2 Antibody industry.
Chapter 3: Detailed analysis of HER2 Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of HER2 Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of HER2 Antibody in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

191 Pages
1 Market Overview
1.1 Product Definition
1.2 Global HER2 Antibody Market Size, 2020 VS 2024 VS 2031
1.3 Global HER2 Antibody Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 HER2 Antibody Market Dynamics
2.1 HER2 Antibody Industry Trends
2.2 HER2 Antibody Industry Drivers
2.3 HER2 Antibody Industry Opportunities and Challenges
2.4 HER2 Antibody Industry Restraints
3 HER2 Antibody Market by Company
3.1 Global HER2 Antibody Company Revenue Ranking in 2024
3.2 Global HER2 Antibody Revenue by Company (2020-2025)
3.3 Global HER2 Antibody Company Ranking (2023-2025)
3.4 Global HER2 Antibody Company Manufacturing Base and Headquarters
3.5 Global HER2 Antibody Company Product Type and Application
3.6 Global HER2 Antibody Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global HER2 Antibody Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 HER2 Antibody Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 HER2 Antibody Market by Type
4.1 HER2 Antibody Type Introduction
4.1.1 Ado-trastuzumab Emtansine
4.1.2 Lapatinib
4.1.3 Pertuzumab
4.1.4 Trastuzumab
4.1.5 Everolimus
4.2 Global HER2 Antibody Sales Value by Type
4.2.1 Global HER2 Antibody Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global HER2 Antibody Sales Value by Type (2020-2031)
4.2.3 Global HER2 Antibody Sales Value Share by Type (2020-2031)
5 HER2 Antibody Market by Application
5.1 HER2 Antibody Application Introduction
5.1.1 Hospital
5.1.2 Medical Center
5.2 Global HER2 Antibody Sales Value by Application
5.2.1 Global HER2 Antibody Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global HER2 Antibody Sales Value by Application (2020-2031)
5.2.3 Global HER2 Antibody Sales Value Share by Application (2020-2031)
6 HER2 Antibody Regional Value Analysis
6.1 Global HER2 Antibody Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global HER2 Antibody Sales Value by Region (2020-2031)
6.2.1 Global HER2 Antibody Sales Value by Region: 2020-2025
6.2.2 Global HER2 Antibody Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America HER2 Antibody Sales Value (2020-2031)
6.3.2 North America HER2 Antibody Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe HER2 Antibody Sales Value (2020-2031)
6.4.2 Europe HER2 Antibody Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific HER2 Antibody Sales Value (2020-2031)
6.5.2 Asia-Pacific HER2 Antibody Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America HER2 Antibody Sales Value (2020-2031)
6.6.2 South America HER2 Antibody Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa HER2 Antibody Sales Value (2020-2031)
6.7.2 Middle East & Africa HER2 Antibody Sales Value Share by Country, 2024 VS 2031
7 HER2 Antibody Country-level Value Analysis
7.1 Global HER2 Antibody Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global HER2 Antibody Sales Value by Country (2020-2031)
7.2.1 Global HER2 Antibody Sales Value by Country (2020-2025)
7.2.2 Global HER2 Antibody Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA HER2 Antibody Sales Value Growth Rate (2020-2031)
7.3.2 USA HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.3.3 USA HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada HER2 Antibody Sales Value Growth Rate (2020-2031)
7.4.2 Canada HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico HER2 Antibody Sales Value Growth Rate (2020-2031)
7.5.2 Mexico HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany HER2 Antibody Sales Value Growth Rate (2020-2031)
7.6.2 Germany HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France HER2 Antibody Sales Value Growth Rate (2020-2031)
7.7.2 France HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.7.3 France HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. HER2 Antibody Sales Value Growth Rate (2020-2031)
7.8.2 U.K. HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy HER2 Antibody Sales Value Growth Rate (2020-2031)
7.9.2 Italy HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain HER2 Antibody Sales Value Growth Rate (2020-2031)
7.10.2 Spain HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia HER2 Antibody Sales Value Growth Rate (2020-2031)
7.11.2 Russia HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands HER2 Antibody Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries HER2 Antibody Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China HER2 Antibody Sales Value Growth Rate (2020-2031)
7.14.2 China HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.14.3 China HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan HER2 Antibody Sales Value Growth Rate (2020-2031)
7.15.2 Japan HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea HER2 Antibody Sales Value Growth Rate (2020-2031)
7.16.2 South Korea HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India HER2 Antibody Sales Value Growth Rate (2020-2031)
7.17.2 India HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.17.3 India HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia HER2 Antibody Sales Value Growth Rate (2020-2031)
7.18.2 Australia HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia HER2 Antibody Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil HER2 Antibody Sales Value Growth Rate (2020-2031)
7.20.2 Brazil HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina HER2 Antibody Sales Value Growth Rate (2020-2031)
7.21.2 Argentina HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile HER2 Antibody Sales Value Growth Rate (2020-2031)
7.22.2 Chile HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia HER2 Antibody Sales Value Growth Rate (2020-2031)
7.23.2 Colombia HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru HER2 Antibody Sales Value Growth Rate (2020-2031)
7.24.2 Peru HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia HER2 Antibody Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel HER2 Antibody Sales Value Growth Rate (2020-2031)
7.26.2 Israel HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE HER2 Antibody Sales Value Growth Rate (2020-2031)
7.27.2 UAE HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey HER2 Antibody Sales Value Growth Rate (2020-2031)
7.28.2 Turkey HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran HER2 Antibody Sales Value Growth Rate (2020-2031)
7.29.2 Iran HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran HER2 Antibody Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt HER2 Antibody Sales Value Growth Rate (2020-2031)
7.30.2 Egypt HER2 Antibody Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt HER2 Antibody Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Novartis AG
8.1.1 Novartis AG Comapny Information
8.1.2 Novartis AG Business Overview
8.1.3 Novartis AG HER2 Antibody Revenue and Gross Margin (2020-2025)
8.1.4 Novartis AG HER2 Antibody Product Portfolio
8.1.5 Novartis AG Recent Developments
8.2 Pfizer
8.2.1 Pfizer Comapny Information
8.2.2 Pfizer Business Overview
8.2.3 Pfizer HER2 Antibody Revenue and Gross Margin (2020-2025)
8.2.4 Pfizer HER2 Antibody Product Portfolio
8.2.5 Pfizer Recent Developments
8.3 InvivoGen
8.3.1 InvivoGen Comapny Information
8.3.2 InvivoGen Business Overview
8.3.3 InvivoGen HER2 Antibody Revenue and Gross Margin (2020-2025)
8.3.4 InvivoGen HER2 Antibody Product Portfolio
8.3.5 InvivoGen Recent Developments
8.4 Genentech Inc
8.4.1 Genentech Inc Comapny Information
8.4.2 Genentech Inc Business Overview
8.4.3 Genentech Inc HER2 Antibody Revenue and Gross Margin (2020-2025)
8.4.4 Genentech Inc HER2 Antibody Product Portfolio
8.4.5 Genentech Inc Recent Developments
8.5 Celltrion
8.5.1 Celltrion Comapny Information
8.5.2 Celltrion Business Overview
8.5.3 Celltrion HER2 Antibody Revenue and Gross Margin (2020-2025)
8.5.4 Celltrion HER2 Antibody Product Portfolio
8.5.5 Celltrion Recent Developments
8.6 Bio-Techne
8.6.1 Bio-Techne Comapny Information
8.6.2 Bio-Techne Business Overview
8.6.3 Bio-Techne HER2 Antibody Revenue and Gross Margin (2020-2025)
8.6.4 Bio-Techne HER2 Antibody Product Portfolio
8.6.5 Bio-Techne Recent Developments
8.7 Biocon Limited
8.7.1 Biocon Limited Comapny Information
8.7.2 Biocon Limited Business Overview
8.7.3 Biocon Limited HER2 Antibody Revenue and Gross Margin (2020-2025)
8.7.4 Biocon Limited HER2 Antibody Product Portfolio
8.7.5 Biocon Limited Recent Developments
8.8 Abnova Corporation
8.8.1 Abnova Corporation Comapny Information
8.8.2 Abnova Corporation Business Overview
8.8.3 Abnova Corporation HER2 Antibody Revenue and Gross Margin (2020-2025)
8.8.4 Abnova Corporation HER2 Antibody Product Portfolio
8.8.5 Abnova Corporation Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.